An interventional study of Scalp Block with Bupivacaine in Regional Anesthesia Morbidity, Supratentorial Brain Tumor and Acute Pain, sponsored by Cairo University. Recruiting at 2 sites in Egypt. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Acute Pain with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Acute Pain · Egypt.
Among the 40 studies in Acute Pain with a site in Egypt, this one is the 13th largest by planned enrollment, is one of 2 that started in 2026, is one of 28 with no phase, and was the 39th registered.
1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →6 of the 40 studies in Acute Pain with a site in Egypt are open now. Recruiting first, the newest first:
Mansoura University · Sites in Egypt
Ages 21–65 · Women only
Al-Azhar University · Sites in Egypt
Ages 21–35 · Women only
South Egypt Cancer Institute · Sites in Egypt
Ages 18–70
Assiut University · Sites in Egypt
Ages 18–50
Mansoura University · Sites in Egypt
Ages 6–12
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 20 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 4 · Phase 4 3
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 86 across 905 interventional studies indexed under Acute Pain.
Median enrollment 77 across the 40 interventional studies. Of the 24 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 40 have an industry lead sponsor. The 10 most frequent:
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Cairo University has 3 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
2 of the studies in Acute Pain with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05750992Al-Azhar UniversityUltrasound Guided TAPB vs Surgical TAPB With Bupivacaine in Cesarean Section | 2026-12-30 |
| NCT06263907Mansoura UniversityStellate Ganglion Block for Prevention of Post Mastectomy Depression | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Acute Pain with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Supratentorial brain tumor surgeries are associated with significant nociceptive stimulation and postoperative pain, which may adversely affect patient outcomes. Scalp block has emerged as an effective regional anesthetic technique to improve analgesia and reduce opioid consumption.
Objective: To compare efficacy of ketamine versus dexmedetomidine as adjuvants to bupivacaine in scalp blocks for supratentorial brain tumor surgeries, focusing on analgesia, opioid consumption, and hemodynamic stability.
Methods:
This randomized double-blinded controlled trial included 80 patients undergoing supratentorial tumor excision, allocated equally into two groups: Group K received bupivacaine with ketamine (2 mg/kg), and Group D received bupivacaine with dexmedetomidine (1 µg/kg). Intraoperative hemodynamics, fentanyl consumption, postoperative pain scores (NRS), analgesic requirements, and complications were assessed.
The study was designed as a prospective, double-blind, randomized controlled clinical trial to evaluate efficacy of Ketamine versus Dexmedetomidine as an adjuvant to Bupivacaine in Scalp Block in Adults undergoing Supratentorial Brain Tumor Excision Surgeries for Hemodynamic and Pain Control.
The study was carried out in neurosurgery operating rooms at Cairo University Hospital, Faculty of Medicine, Cairo University.
The study was approved by the Ethics Committee of Faculty of Medicine, Cairo University, MS-483-2025 Egypt. The trial was preregistered on clinicaltrials.gov, NCT06168903.Written informed consent was obtained from all patients. The Consolidated Standards of Reporting Trials (CONSORT) guidelines were adhered Informed written consent was obtained from each patient. There are adequate provisions to maintain participants' privacy and confidentiality of the data.
Randomization will be performed using computer-generated numbers. Allocation concealment will be maintained using serially numbered, opaque, and sealed envelopes. Investigators will remain blind to the sequence, with group assignments contained in envelopes marked only with case numbers. Before each case, a study nurse or assistant will open the corresponding numbered envelope to reveal the patient's group assignment.
Study Protocol:
Patients visited the pre-anesthesia room before the procedure. All patients received explanation of Numerical Rating Scale (NRS) for pain assessment, which ranges from 0 (no pain) to 10 (most severe pain) [17].
Standard monitoring was applied, including electrocardiography (ECG), non-invasive, invasive blood pressure, and Oxygen Saturation (SaO₂), and baseline vital signs were recorded, including heart rate, systolic and diastolic blood pressure, mean arterial pressure, and oxygen saturation.
Anesthesia was induced with intravenous propofol 2 mg/kg, fentanyl 2 µg/kg, and atracurium 0.5 mg/kg, with mask ventilation for 3 minutes followed by tracheal intubation. Intraoperative signs of inadequate analgesia, such as tachycardia or hypertension exceeding 20% of baseline, were managed with additional 50 µg doses of fentanyl, and total fentanyl consumption was recorded. Anesthesia was maintained using intermittent positive pressure ventilation with isoflurane 0.8-1.2 MAC in an oxygen/air mixture, and atracurium infusion 0.5 mg/kg, while end-tidal CO₂ was monitored.
After induction, bilateral scalp blocks were performed using a 23G needle, with local anesthetic infiltrated around supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, lesser occipital, greater occipital, and great auricular nerves, 2-3 mL per nerve.
Scalp Block Techniques Supraorbital Nerve Block Patient was seated with the head slightly forward and eyes closed. The supraorbital notch was palpated, and a needle was inserted approximately 1 cm above the notch. 2 ml of local anesthetic were injected at this site.
Supratrochlear Nerve Block With the patient in the same position, the injection site was located one finger's breadth medial to the supraorbital nerve. The needle was redirected medially, and 3 mL of local anesthetic was administered.
Zygomaticotemporal Nerve Block The patient's head was turned so that the target side was facing upward. Landmarks included the orbital rim and zygomatic arch. A dual injection technique was used, with 1 mL injected deeply and 2 mL subcutaneously.
Auriculotemporal Nerve Block The injection site was 1-1.5 cm anterior to the ear, above the tragus, taking care to avoid superficial temporal artery. 3ml of local anesthetic were injected subcutaneously.
Greater Occipital Nerve Block With the head turned or the patient seated, the occipital artery was palpated, approximately 3-4 cm lateral to the external occipital protuberance. The needle was inserted perpendicular to the skin medial to the artery, and 3 mL of local anesthetic was injected subcutaneously.
Lesser Occipital Nerve Block Injection site was located about 2.5 cm lateral to the greater occipital nerve block site. 3 ml of local anesthetic were administered subcutaneously.
Great Auricular Nerve Block (Postauricular Branches) The injection site was 1.5 cm posterior to the ear at the level of the tragus. The needle was inserted perpendicular to the bone, withdrawn slightly, and 3 mL of local anesthetic was injected subcutaneously [5].
Hemodynamic Monitoring HR and BP were recorded baseline before induction, 1 and 5 minutes after induction, at intubation, 5 minutes after the scalp block, 5 minutes after pin insertion, 5minutes after skin incision, at 15min, 20min, 25min, 30min,35min, 40min,60min, 95min, 3hour, 4hour and after extubating as well as in post-anesthesia care unit (PACU) and upon arrival in surgical ICU.
Deviations from baseline were managed according to protocol:
In PACU, standard monitoring was continued, pain was assessed using NRS. Patients were discharged when modified Aldrete Score exceeded 9 [18].
Paracetamol and ketorolac were given as rescue analgesia when NRS score was more than 4. The time from extubating to the first analgesic request was recorded, and total postoperative analgesic consumption was documented.
Any hemodynamic instability, including hypertension, tachycardia, bradycardia, or hypotension, as well as nausea, vomiting, and other complications, were recorded.
Hemodynamic monitoring (MAP in mmHg) was Pain assessment using NRS (0-10) was conducted upon PACU arrival, 2, 4, 6, 8, 12and 24 hours postop
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
and operation time: less than 6 hours.
Exclusion Criteria:
Postictal state or uncontrolled/recurrent seizures, known allergy to dexmedetomidine or ketamine, difficult intubation (Mallampati score > III) or multiple intubation attempts, operation duration > 6 hours, renal dysfunction (creatinine > 1.2 mg/dL, BUN > 20 mg/dL), heart block and patients with chronic headache disorders or those receiving chronic analgesic therapy (for >3 months) were excluded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 1 µg/kg of dexmedetomidine, with the remainder filled with saline.
Drug: Scalp Block with Bupivacaine
Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 2 mg/kg of ketamine, with the rest filled with saline. The syringes will be prepared by an anesthesia technician and handed blindly to the anesthetist to administer the block.
Drug: Scalp Block with Bupivacaine
After induction, bilateral scalp blocks were performed using a 23G needle, with local anesthetic infiltrated around supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, lesser occipital, greater occipital, and great auricular nerves, 2-3 mL per nerve.
Analgesic efficacy of dexmedetomidine versus ketamine as adjuvants in scalp blocks
Compare analgesic efficacy of dexmedetomidine versus ketamine as adjuvants in scalp blocks for supratentorial tumor resection by measuring total intraoperative fentanyl consumption (in µg).
Time frame: 6 hours
Compare the time duration after extubating to request the first analgesia.
Compare the time duration after extubating to request the first analgesia.
Time frame: 24 hours
Total analgesic consumption.
Total analgesic consumption in intraoperative and postoperative period till 24 hours.
Time frame: 24 hours
NRS pain score
NRS pain score at various time points in the postoperative period till 24 hours.
Time frame: 24 hours
Nausea and vomiting
Nausea and vomiting incidence
Time frame: 24 hours
Side effects
Systemic side effects of ketamine (sedation, hallucinations, nystagmus).
Time frame: 24 hours
Side effects
Systemic side effects of dexmedetomidine (bradycardia).
Time frame: 24 hours
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jul 2026, 6 months after the start.
Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 6 months is below that.
Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.